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Is Anti–Tumor Necrosis
Factor Therapy Associated
with Increased Mortality in
Patients with Severe Sepsis
Caused by Pneumonia?
To the Editor—We read with great inter-
est the article by Rijneveld et al. [1] sug-
gesting that anti–tumor necrosis factor
(TNF) therapy may impair the therapeu-
tic efficacy of betalactam antibiotics dur-
ing pneumococcal pneumonia. Moreover,
in the Discussion, Rijneveld et al. raised
the question of whether patients with se-
vere sepsis caused by bacterial pneumonia
who are enrolled in clinical trials inves-
tigating anti-TNF agents experience in-
creased mortality because of the anti-TNF
treatment.
To test this hypothesis, we conducted a
retrospective cohort study including 1342
patients with severe sepsis and early septic
shock who were enrolled in a double-
blind, placebo-controlled phase III trial to
determine the safety and efficacy of p55
IgG TNF-receptor fusion protein (lener-
cept) [2]. Mortality was analyzed by mul-
tivariate Cox proportional-hazards regres-
sion. Results of standard tests showed no
disagreement with the proportional-haz-
ards assumption.
A total of 365 patients (27%) had bac-
terial pneumonia causing severe sepsis or
septic shock. There were 57 deaths (32%)
among the 179 patients receiving lener-
cept, compared with 63 deaths (34%)
among the 186 patients receiving placebo
(crude hazard ratio [HR], 0.9; 95% con-
fidence interval [CI], 0.6–1.3). The risk of
death remained unchanged after adjust-
ments for differences in the appropriate-
ness of the initial antibiotic treatment, in
the number of baseline organ dysfunc-
tions, and in the severity of illness.
We also observed 92 patients with pneu-
mococcal pneumonia who received beta-
lactam antibiotics as their initial anti-
microbial treatment. In agreement with
the findings cited above, exposure to le-
nercept was not found to be associated
with a significantly increased risk of death
(adjusted HR, 0.7; 95% CI, 0.3–1.6), after
patients were stratified by receipt of ei-
ther lenercept ( ) or placebo (nnp 42
p50) and after adjustments for poten-
tial confounders. In a separate conditional
regression analysis, which grouped pa-
tients either by center or country (to avoid
confounding by possible cluster effects),
we confirmed the absence of an associa-
tion between anti-TNF treatment and in-
creased risk of death in patients with sepsis
caused by pneumonia.
These data suggest that the reported as-
sociation between anti-TNF treatment and
adverse outcomes in murine pneumococ-
cal pneumonia may not be observed in
patients with severe sepsis caused by bac-
terial pneumonia. Several reasons may ex-
plain the discrepancy between our find-
ings and the results reported by Rijneveld
et al. [1]. First, the size of our sample of
patients with sepsis caused by pneumo-
coccal pneumonia may have been too
small to show a deleterious effect of anti-
TNF treatment. However, the 95% CI of
our estimate indicates that, if such an ef-
fect exists, its magnitude and clinical im-
portance would be rather small. Second,
the relatively low dosage and weak phar-
macologic effect of the anti-TNF agent in
our study may have prevented adverse ef-
fects. Higher doses of similar anti-TNF
agents have been shown to induce adverse
outcomes and to be associated with in-
creased mortality [3]. Finally, the timing
of the administration of anti-TNF and an-
tibiotics in Rijneveld et al.’s animal exper-
iment may have been different from the
treatment schedule in our clinical trial. Al-
though Rijneveld et al. addressed this lim-
itation, in a real-life clinical situation the
administration of anti-TNF agents may oc-
cur much later in the course of the anti-
inflammatory response, compared with the
animal experiment.
Overall, we believe that the study con-
ducted by Rijneveld et al. is valuable in
that it shows the potential hazards of
blocking local TNF production in mice
with pneumococcal pneumonia. However,
caution should be applied when these
findings are generalized and compared
with the results of previously published
clinical trials performed in humans.
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